- Conditions
- Low Back Pain
- Interventions
- Hydrocodone ER, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 625 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 87
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 71 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 841–864
of 6,846
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Low Back Pain
- Interventions
- Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo
- Drug
- Lead sponsor
- Purdue Pharma LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 149
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Foley, Alabama + 114 more
- Conditions
- Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
- Interventions
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2026
- U.S. locations
- 223
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 157 more
- Conditions
- Hepatitis C
- Interventions
- DCV/ASV/BMS-791325
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 42
- States / cities
- La Jolla, California • San Diego, California • San Francisco, California + 37 more
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 568 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 81
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more
- Conditions
- Solid Tumor, Adult
- Interventions
- ADA-011, PD(L)-1 inhibitor
- Drug
- Lead sponsor
- Adanate, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Orlando, Florida • Durham, North Carolina + 2 more
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Gefitinib, methotrexate
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Palm Springs, California + 23 more
- Conditions
- Atrial Fibrillation
- Interventions
- Endoscopic Ablation System, Standard Anti-arrhythmic Drug (AAD) Therapy
- Device · Drug
- Lead sponsor
- CardioFocus
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Sacramento, California • San Francisco, California + 15 more
- Conditions
- Tibial Nonunions
- Interventions
- Surgical implantation of OP-1 device or autograft bone graft material
- Device
- Lead sponsor
- Olympus Biotech Corporation
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 1999
- U.S. locations
- 18
- States / cities
- Mesa, Arizona • Modesto, California • San Diego, California + 15 more
- Conditions
- Antithrombotic
- Interventions
- Enoxaparin, unfractionated heparin (UFH), BMS-986177
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 3
- States / cities
- Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota
- Conditions
- Nonrestorative Sleep
- Interventions
- PD 0200390, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 52
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 45 more
- Conditions
- Cystic Fibrosis, Lung Infection, Pseudomonas Aeruginosa
- Interventions
- AZLI 75 mg three times daily (TID), Placebo three times daily (TID)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 26 more
- Conditions
- Proteinuric Kidney Disease
- Interventions
- MZE829
- Drug
- Lead sponsor
- Maze Therapeutics
- Industry
- Eligibility
- 18 Years to 68 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 68
- States / cities
- Decatur, Alabama • Huntsville, Alabama • Montgomery, Alabama + 56 more
- Conditions
- Hepatic Impairment
- Interventions
- Danicopan
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Essential Tremor
- Interventions
- SAGE-217, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 26
- States / cities
- Anniston, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 23 more
- Conditions
- Depression, Acute Pain, Chronic Pain
- Interventions
- Pharmacogenetic testing, Clinical decisions support
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 8 Years and older
- Enrollment
- 4,284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 14
- States / cities
- Wilmington, Delaware • Gainesville, Florida • Jacksonville, Florida + 6 more
- Conditions
- Related Hematopoietic Stem Cell Donors
- Interventions
- Not listed
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- Not listed
- Enrollment
- 1,812 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • San Diego, California • San Francisco, California + 44 more
- Conditions
- Major Depressive Disorder
- Interventions
- Escitalopram
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Boulder, Colorado • Denver, Colorado + 15 more
- Conditions
- Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
- Interventions
- Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
- Biological · Other · Drug
- Lead sponsor
- Beat AML, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2032
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
- Interventions
- L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone, vincristine sulfate, cytarabine, prednisone, bortezomib, pegaspargase, methotrexate, etoposide phosphate, cyclophosphamide, filgrastim, leucovorin calcium, laboratory biomarker analysis, High Dose MTX
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 31 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 157
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 124 more
- Conditions
- Achalasia, Esophageal Spasm, Diffuse, Gastroparesis, Swallowing Disorder, Zenker Diverticulum
- Interventions
- Not listed
- Lead sponsor
- AdventHealth
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Cystic Fibrosis
- Interventions
- ELX/TEZ/IVA, IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 458 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 42 more
- Conditions
- Cystic Fibrosis
- Interventions
- MP-376 (Levofloxacin solution for Inhalation)
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years to 16 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 6
- States / cities
- Mobile, Alabama • San Diego, California • Orlando, Florida + 3 more
- Conditions
- Depressive Disorder, Major
- Interventions
- Aticaprant
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 871 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 87
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 70 more